Why is Fredun Pharma falling/rising?

As of 15-Sep, Fredun Pharmaceuticals Ltd is experiencing a price increase, currently at 1,228.95, reflecting a rise of 14.95 or 1.23%. The stock has shown a trend reversal, gaining after four consecutive days of decline, and today it outperformed its sector by 1.68%. Over the past week, the stock has decreased by 7.27%, but it has performed well over the past month with a return of 17.36%. The company has demonstrated strong financial health, with net sales growing at an annual rate of 38.16% and operating profit at 56.18%. Additionally, it has reported positive results for the last five consecutive quarters, contributing to its favorable valuation compared to peers.
In the broader market context, while the stock has outperformed the benchmark BSE500, which has seen a negative return of -3.45% over the past year, Fredun Pharmaceuticals has generated a remarkable return of 56.16% during the same period. This significant outperformance highlights the company's resilience and attractiveness to investors despite the broader market challenges. However, it is worth noting that domestic mutual funds hold no stake in the company, which may indicate a lack of confidence in its current valuation or business prospects.